InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (2 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the detailed record of transactions filed by Orwin John A, Chairman & CEO. Officer active across 4 companies, notably Travere Therapeutics, Inc.. In total, 18 disclosures have been published. Breakdown: 1 buy · 2 sells. Total volume traded: €45k. Activity tracked since 14 May 2021. The latest transaction was filed on 15 September 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Orwin John A
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations18 total
6,030 sharesCommon StockSEC:0001477384-26-000010:0
1,300 shares0Common StockSEC:0001477384-25-000004:0
6,030 shares0Common StockSEC:0001415889-25-017589:0
6,500 shares0Common StockSEC:0001415889-25-013501:0
1,300 shares0Common StockSEC:0001415889-24-023552:0
2,035 shares0Common StockSEC:0001415889-24-017508:0
6,500 shares0Common StockSEC:0001415889-24-012849:0
1 shares@ US$0.010.0% of flowSeries A Junior Preferred StockSEC:0001415889-24-011059:0
Canonical exit: 10 Jul 2024 (T+90)
22,951 shares@ US$0.374617.5% of flowClass A Common StockSEC:0001415889-24-010243:0
29,003 shares@ US$229.00100.0% of flowCommon StockSEC:0000950170-23-070863:0
2,044 shares0Common StockSEC:0001203311-23-000061:0
4,500 shares0Common StockSEC:0001209191-23-030956:0
20,908 shares@ US$1.775282.5% of flowClass A Common StockSEC:0001209191-22-050778:0
1,503 shares0Common StockSEC:0000899243-22-018465:0
3,000 shares0Common StockSEC:0001209191-22-028699:0
115,400 shares0Class A Common StockSEC:0001209191-21-055809:0
3,000 shares0Common StockSEC:0001209191-21-033847:0
1,402 shares0Common StockSEC:0001203311-21-000032:0
18 of 18 declarations
About Orwin John A
Orwin John A is President and Chief Executive Officer. Across 18 filings, the 18 sampled filings cover the period from 2021-05-18 to 2026-06-17 and show €0 of buys and €6,146,276 of sells, mainly through Seagen Inc. and Atreca, Inc.; the recent filings also include transactions categorized as Attribution and other at Anaptysbio, INC.
